In conclusion, although emerging evidence suggests that TMEM16A may serve as a valuable target in prostate cancer treatment, current research is limited by methodological discrepancies, a lack of mechanistic clarity, and an overreliance on in vitro studies. Here, ANO1 is linked to Familial prostate cancer.